NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a...

... 801, a combination drug for the treatment of cognitive disorders in diseases such as ADD/ADHD, schizophrenia and Alzheimer's disease. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona,

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/NeuroDerm-Announces-Enrollment-in-a-Phase-2-Study-/ArticleNewsFeed/Article/detail/810582?ref=25